 |
|
|
|
|
|
|
||
|
List of Diseases Treated by SCT
|
Spinal Cord Injuries, Old or Recent, Parkinson's & Neurological Diseases and Their Treatment by Stem Cell Transplantation
Parkinson's disease became a landmark in history of stem cell transplantation (SCT) when a series of such treatments was carried out in Mexico City in 1980's on a group of patients suffering from an advanced stage of this incurable illness with various degrees of success (if you click on the above SCT link you will open our homepage where you learn more about this therapy and how to order our stem cell transplants) A term neurotransplantation has been coined for such treatment. Treatment of diseases of central nervous system by stem cell transplantation requires also an implantation into the brain and spinal cord, even though not necessarily into the body of these organs. The implantation can be 'intrathecal', i.e. into the cerebrospinal fluid, a vitally important fluid for the function of central nervous system, which circulates in the preformed spaces around and in the brain and spinal cord. This is the least traumatic method of neurotransplantation as there is but minimal trauma to the brain tissues of the patient (i.e. intraventricular implantation), and no trauma when stem cells are implanted into spinal canal. Spinal cord injuries, old or recent, have been considered a supreme challenge. Prior to July 1, 2005, we have treated 20 patients with old spinal cord injuries and 17 of them had an improvement after only one course of intrathecal stem cell transplantation. The existing treatments of all degenerative diseases suffer from one common problem: no attempt at regeneration of degenerating cells of diseased organs and tissues is ever made. The sole treatment capable of direct stimulation of regeneration is stem cell transplantation. And that applies primarily to degenerative diseases of central nervous system. Treatment of neurological diseases has always been a sad chapter of medicine due to lack of effective therapy for great majority of diseases. Here Parkinson's disease has been a bright exception because of availability of levodopa therapy, which controls symptoms of disease quite well for several years. Ultimately every patient with Parkinson's disease will reach a stage when medications which stimulate production of a neurotransmitter dopamine by neurons of the pertinent part of the brain stop working, whereupon life becomes a pure misery. Ideally, already before that happens, each patient should undergo stem cell transplantation. Unfortunately neurotransplantation treatment of Parkinson's disease has not been as succesful in clinical practice (rate of success > 5%) as under experimental conditions (rate of success ~ 95%). The enormous discrepancy between the high success of neurotransplantation in animal experiment and low success in clinical practice, is unusual. The recently completed U.S. National Institute of Health clinical trial ended in a failure. Part of the problem was that researchers were more concerned about fulfilling requirements of double-blind study, including unethical and immoral 'sham surgery', than to help desperate patients. Stem cell transplantation, usually reserved to untreatable or incurable diseases, is hardly suitable for 'double-blind' clinical studies. Scientists believed that the reason for such lack of success was that the neurons in adult human brain and spinal cord could not recover from serious damage. And once dead, neurons could not be replaced. In the last few years stem cells were found in three different parts of the adult brain, which implies that regeneration of damaged brain tissue should be possible, and that applies to neurons that carry nerve impulses, as well as to supporting glial cells, without which neurons cannot survive. Since it has been known that stem cell transplantation is the sole treatment available to medicine today to directly regenerate cells, tissues and organs, the unfortunate neurological patients have hope again, as our greatsuccess in the treatment of old spinal cord injury patients have proved beyond any doubt. (biocell@stem-cell-transplantation.com) Since 1998 we have made our stem cell transplants available to
with worldwide delivery. This was a result of 25+ years' of research, GMP ('good manufacturing practice'), and clinical experience with neurotransplantation in ~ 500 patients suffering from old spinal cord injuries, Parkinson's disease, deep coma of various cause, and variety of degenerative neurological diseases. Our success with several patients with Parkinson's disease was ~ 95%. In one study published in 1994 we used a combination of human fetal and Drosophila brain tissues for neurotransplantation. We treated over 400 patients with a variety of advanced degenerative diseases of spinal cord and brain stem, such as amyotrophic lateral sclerosis, multiple sclerosis, Friedreich's ataxia, other spino-cerebellar degenerations, etc., and lately also patients with old spinal cord injuries, via implantation of fetal brain cells into the spinal canal. In another published study of 14 patients, treated by implantation of fetal brain cells into the spinal canal, there was a group of 9 patients that were in deep coma for several days, due to severe brain hemorrhage, severe head injury, of which two patients (anaphylactic shock after antibiotic injection; general anesthesia mishap during cataract surgery) passed through clinical death. All 9 patients woke up from coma within 24 hours after stem cell transplantation. An implantation of fetal brain cells (with stem cells) have been tried during the past 15 years to help patients with a variety of neurological diseases, for which treatment is not known, such as genetic diseases, injuries, cerebrovascular accidents, etc., or for which treatment had lost its effectiveness in the course of the progression of illness, such as Parkinson’s disease, etc.), but the success rate has been very low. The main reason has been a very low viability of implanted human fetal brain cells, which have been used 'fresh', rather than prepared by tissue culture. Unless human fetal brain cells are kept in tissue culture up until the last moment before surgery, the viability of implanted cells will always be a big unknown. To implant dead brain cells is meaningless. In the recent clinical trial in Florida 10 patients with Parkinson’s disease received transplantation of fetal neural cells of animal origin in order to eliminate the problem of viability. This trial proved that xeno-neuro-transplantation is tolerated equally well by patients as when human fetal brain cells are implanted. The use of stem cell transplantation as a treatment of spinal cord injuries and all described neurological diseases can be studied in a textbook of E. Michael Molnar, M.D. "Stem Cell Transplantation, a Textbook of Stem Cell Xeno-Transplantation", published by Medical And Engineering Publishers, Inc., Washington, D.C., in February 2006, the first textbook for medical profession and students in the world about this subject. Click on www.mepublishers.com
(biocell@stem-cell-transplantation.com)
|
|
 |
Our know-how, based on 25+ years of experience, permits us to offer you in this web site
as well as a possibility to
(Long distance consultation will soon be available via telemedicine link as well.) Whenever you contact us on this web site in order to
we will respond promptly. Besides that we assign each prospective client an ID code, so that there is no need to use the patient's name in future communications, or on vials containing the patient's stem cell transplants. The combined effect of such steps is that sensitive medical data will not get into the wrong hands. |
|
|
|
||
| ABOUT BCRO | WARRANTY/REPLACEMENT | DISCLAIMER | PRIVACY STATEMENT | |
| Copyright Bio-Cellular Research Organization LLC | ||||
| Updated: July 2005 | ||||
